Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Amortizatization of Intangibles: 2012-2024

Historic Amortizatization of Intangibles for Akebia Therapeutics (AKBA) over the last 13 years, with Dec 2024 value amounting to $36.0 million.

  • Akebia Therapeutics' Amortizatization of Intangibles changed negligibly% to $9.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $36.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $36.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Amortizatization of Intangibles is $36.0 million, which was down 0.00% from $36.0 million recorded in FY2023.
  • Akebia Therapeutics' Amortizatization of Intangibles' 5-year high stood at $36.0 million during FY2021, with a 5-year trough of $32.6 million in FY2020.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $36.0 million (2024), whereas its average is $36.0 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first fell by 10.40% in 2020, then climbed by 10.50% in 2021.
  • Over the past 5 years, Akebia Therapeutics' Amortizatization of Intangibles (Yearly) stood at $32.6 million in 2020, then climbed by 10.50% to $36.0 million in 2021, then remained steady at $36.0 million in 2022, then fell by 0.00% to $36.0 million in 2023, then remained steady at $36.0 million in 2024.